<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336543">
  <stage>Registered</stage>
  <submitdate>15/02/2011</submitdate>
  <approvaldate>21/02/2011</approvaldate>
  <actrnumber>ACTRN12611000198921</actrnumber>
  <trial_identification>
    <studytitle>Multicenter trial for induction of labor with the combination of misoprostol and mechanical ripening of the cervix</studytitle>
    <scientifictitle>Randomized multicenter study of a combination of oral misoprostol (OM) and mechanical dilation of the cervix by double balloon device (COOK CRB [Cervical Ripening Balloon]) versus OM alone to improve efficacy in inducing labor.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Efficacy of two different methods of labor induction at term - OM and Cook CRB versus OM alone.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Combination of OM and mechanical dilation with a double-balloon catheter for cervical ripening (COOK CRB) is used.

Each participating hospital uses its own misoprostol regime plus CRB for a maximum of 12 hours the first day.

e.g. the regime of the primary study unit:
First day: OM 50 microg with repeat doses 4 and 8 hours later if necessary plus CRB for a maximum of 12 hours
Second day: OM 100 microg with repeat doses 4 and 8 hours later if necessary
Third day: misoprostol 50 microg vaginally with repeat doses 4 and 8 hours later if necessary</interventions>
    <comparator>Only the misoprostol regime.

e.g. the regime of the primary study unit:
First day: OM 50 microg with repeat doses 4 and 8 hours
later if necessary 
Second day: OM 100 microg with repeat doses 4 and 8 hours later if necessary 
Third day: misoprostol 50 microg vaginally with repeat doses 4 and 8 hours later if necessary</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The rate of failure to induce labor, defined as no delivery within 48 hours.</outcome>
      <timepoint>Immediately after birth.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The time of induction of labor to birth.</outcome>
      <timepoint>Immediately after birth.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>singleton pregnancy at term greater than 259 days of gestation, vertex presentation, indication for induction of labor, and an unfavorable cervix (Bishop score &lt; 8)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Premature Rupture of Membranes (PROM),
contraindication for labor induction with misoprostol (e.g. placenta previa, previous cesarean sections),
cases of structural or chromosomal malformation,
intrauterine fetal death.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>14/02/2011</anticipatedstartdate>
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/08/2012</actualenddate>
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Sven Kehl</primarysponsorname>
    <primarysponsoraddress>University Hospital Mannheim
Department of Obstetrics and Gynecology

Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Australian</primarysponsoraddress>
    <primarysponsorcountry>Germany</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University Hospital Mannheim Department of Obstetrics and Gynecology</fundingname>
      <fundingaddress>Theodor-Kutzer-Ufer 1-3
68167 Mannheim</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Induction of labor is a common obstetric procedure that is being more widely used nowadays than ever before. Pharmacologic and mechanical methods are used to induce labor. As there are different modes of action, a reduced
induction-to-delivery time can be expected if the pharmacologic and mechanical methods are used simultaneously. The hypothesis is that a combination of pharmacological (oral misoprostol) and mechanical dilation
(CRB - a double balloon device) improve the efficacy of labor induction. In a primary study the combination showed to be beneficial. These results supposed to be checked in a multicenter trial with different misoprostol regimes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sven Kehl</name>
      <address>University Hospital Mannheim
Department of Obstetrics and Gynecology

Theodor-Kutzer-Ufer 1-3
68167 Mannheim</address>
      <phone>0049-621-3832286</phone>
      <fax />
      <email>sven.kehl@gmail.com</email>
      <country>Germany</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sven Kehl</name>
      <address>University Hospital Mannheim
Department of Obstetrics and Gynecology

Theodor-Kutzer-Ufer 1-3
68167 Mannheim</address>
      <phone>0049-621-3832286</phone>
      <fax />
      <email>sven.kehl@gmail.com</email>
      <country>Germany</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sven Kehl</name>
      <address>University Hospital Mannheim Department of Obstetrics and Gynecology Theodor-Kutzer-Ufer 1-3 68167 Mannheim</address>
      <phone>+49-621-3832286</phone>
      <fax />
      <email>sven.kehl@gmail.com</email>
      <country>Germany</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>